Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

AstraZeneca and Daiichi Sankyo’s antibody-drug ... therapies fail, their only option currently is single-agent chemotherapy. “Many of these patients with metastatic breast cancer in TROPION ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer ... stage candidates from AstraZeneca and Radius ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

The drug pipeline—the process through which a potential new drug gets discovered, tested, approved, and marketed—is a ...

QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Understand every aspect of the global economy – and know how to make your next move.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

A perfect storm of scientific, economic, and cultural barriers are holding back immunotherapy's true potential, writes Samir ...